Should You Worry About This Threat to Moderna's Vaccine?
Moderna's (NASDAQ: MRNA) success story is all about its coronavirus vaccine. This is big -- especially considering Moderna didn't have any commercialized products until regulators authorized the vaccine in late December. Investors are hoping this is just the beginning of Moderna's coronavirus vaccine revenue growth.